MYNEO THERAPEUTICS

A little history

myNEO was founded in 2018 by leading biotech entrepreneurs combining expertise from different academic institutions. Cedric Bogaert, Jan Van Den Berghe, and Wim van Criekinge have since then expanded the team with established domain in antigen discovery experts as well as ambitious talent to further grow the company's innovation and developments.

myNEO offices

To date, myNEO has achieved several pivotal milestones in realizing its vision. These include:

  • Development of state-of-the-art antigen prediction algorithms
  • Discovery of novel, dark antigen targets called camyotopes
  • (Co-)development of novel immunotherapeutics products via strategic collaborations or in-house, leading to 3 separate programs executing successful IND/CTA filings in 2025
  • The publication of high-impact scientific papers
  • ISO and regulatory approval for clinical use of technology
  • Securing valuable intellectual property with multiple patents
  • Receiving several prestigious awards (Most Disruptive Innovator, Forbes 30under30, Rising Star Fast50)
Prof. Timon Vandamme PhD MD

Prof. Timon Vandamme PhD MD

Scientific advisor

Timon Vandamme is a senior consultant in digestive and neuroendocrine oncology at the Antwerp University Hospital and assistant professor at the University of Antwerp. As clinician-researcher, he is performing research in novel biomarkers including circulating tumoral DNA (ctDNA) and innovative immune-modulatory therapy such as anti-cancer vaccines in digestive and neuroendocrine neoplasms (NEN).

Currently, he is holder of a Senior Clinical Investigator (FKM) grant of the Fonds Wetenschappelijk Onderzoek (FWO) at the University of Antwerp. He has authored numerous papers in high-impact journals and is active member of the EORTC GI Tract Cancer Group and the ENETS Translational Working Group.

View LinkedIn profile